ATE173402T1 - Lyophilisierte stammzellenfaktor formulierungen - Google Patents

Lyophilisierte stammzellenfaktor formulierungen

Info

Publication number
ATE173402T1
ATE173402T1 AT95906058T AT95906058T ATE173402T1 AT E173402 T1 ATE173402 T1 AT E173402T1 AT 95906058 T AT95906058 T AT 95906058T AT 95906058 T AT95906058 T AT 95906058T AT E173402 T1 ATE173402 T1 AT E173402T1
Authority
AT
Austria
Prior art keywords
stem cell
cell factor
lyophilized
factor formulations
lyophilized stem
Prior art date
Application number
AT95906058T
Other languages
English (en)
Inventor
Susan I Hershenson
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE173402T1 publication Critical patent/ATE173402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95906058T 1993-12-22 1994-12-21 Lyophilisierte stammzellenfaktor formulierungen ATE173402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/172,507 US6288030B1 (en) 1993-12-22 1993-12-22 Stem cell factor formulations and methods

Publications (1)

Publication Number Publication Date
ATE173402T1 true ATE173402T1 (de) 1998-12-15

Family

ID=22627993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95906058T ATE173402T1 (de) 1993-12-22 1994-12-21 Lyophilisierte stammzellenfaktor formulierungen

Country Status (14)

Country Link
US (4) US6288030B1 (de)
EP (1) EP0732935B1 (de)
CN (1) CN1105575C (de)
AT (1) ATE173402T1 (de)
AU (1) AU696860B2 (de)
CA (1) CA2182970C (de)
DE (1) DE69414723T2 (de)
DK (1) DK0732935T3 (de)
ES (1) ES2123951T3 (de)
HK (1) HK1008815A1 (de)
IL (1) IL112088A (de)
NZ (1) NZ278252A (de)
WO (1) WO1995017206A1 (de)
ZA (1) ZA9410189B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9515839D0 (en) * 1995-08-02 1995-10-04 Q One Biotech Ltd Feline stem cell factor
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6472208B1 (en) * 1999-12-13 2002-10-29 Héma-Québec Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2002220209B2 (en) * 2000-12-06 2006-05-25 Robert J. Hariri Method of collecting placental stem cells
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
EP2336301B1 (de) * 2001-02-14 2014-07-30 Anthrogenesis Corporation Post-partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3963786B2 (ja) * 2002-06-11 2007-08-22 富士通株式会社 情報処理装置
JP2006509770A (ja) * 2002-11-26 2006-03-23 アンソロジェネシス コーポレーション 細胞治療学、細胞治療単位、およびそれらを利用した治療法
US20040219136A1 (en) * 2003-02-13 2004-11-04 Hariri Robert J Use of umbilical cord blood to treat individuals having a disease, disorder or condition
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
BRPI0417186A (pt) * 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
WO2007016562A2 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
CA2856662C (en) 2005-10-13 2017-09-05 Anthrogenesis Corporation Immunomodulation using placental stem cells
EP2471907B1 (de) * 2005-12-29 2018-09-26 Celularity, Inc. Plazentastammzellenpopulationen
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
NZ576194A (en) 2006-10-23 2012-02-24 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
KR20150039214A (ko) 2007-02-12 2015-04-09 안트로제네시스 코포레이션 태반 줄기세포를 이용한 염증 질환의 치료
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
MX2010003217A (es) * 2007-09-26 2010-07-30 Celgene Cellular Therapeutics Celulas angiogenicas de perfundido de placenta humana.
NZ617412A (en) * 2007-09-28 2015-06-26 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
CA2704746A1 (en) * 2007-11-07 2009-05-14 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
KR20210149904A (ko) * 2008-08-20 2021-12-09 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
MX2011001990A (es) * 2008-08-20 2011-03-29 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
CA2734446C (en) * 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
CN102282252B (zh) 2008-11-19 2017-07-04 人类起源公司 羊膜来源的贴壁细胞
EP2375907B1 (de) * 2008-11-21 2019-02-27 Celularity, Inc. Behandlung von krankheiten, störungen oder leiden der lunge mittels plazentazellen
NZ619359A (en) 2009-07-02 2015-07-31 Anthrogenesis Corp Method of producing erythrocytes without feeder cells
CA2787992A1 (en) * 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
EP3088512B1 (de) 2010-04-07 2019-12-11 Celularity, Inc. Verwendung von plazenta-stammzellen zur behandlung von herz- und kreislaufskrankheiten durch förderung der angiogenese
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
CA2804750C (en) 2010-07-13 2022-05-10 Anthrogenesis Corporation Methods of generating natural killer cells
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP3443968A1 (de) 2011-06-01 2019-02-20 Celularity, Inc. Schmerzbehandlung mithilfe von stammzellen aus der plazenta
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
CN115282165A (zh) 2013-02-05 2022-11-04 细胞结构公司 来自胎盘的自然杀伤细胞
PT3334747T (pt) 2015-08-13 2023-12-12 Amgen Inc Formulação de gonadotrofina líquida estável

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
JPS5534001A (en) * 1978-08-28 1980-03-10 Noda Sangyo Kagaku Kenkyusho Stabilization of sarcosine oxidase
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3176491D1 (en) 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
JPS5874617A (ja) 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
JPS58134991A (ja) * 1981-12-28 1983-08-11 Takeda Chem Ind Ltd セラチオペプチタ−ゼの安定化法
JPS59134730A (ja) 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
NZ226170A (en) 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
EP0381345B1 (de) 1989-01-30 1994-07-13 Corint, Ltd. Wässerige Desmopressin-CMC enthaltende Arzneizubereitung
JPH02268681A (ja) * 1989-04-07 1990-11-02 Green Cross Corp:The ウロキナーゼ前駆体の安定化方法及び乾燥製剤
WO1990012029A1 (en) * 1989-04-11 1990-10-18 Immunobiology Research Institute, Inc. Lyophilized peptide formulations
AU6541090A (en) 1989-10-16 1991-05-16 Amgen, Inc. Stem cell factor
EP1241258A3 (de) 1989-10-16 2003-12-10 Amgen Inc. Stamzellfaktor
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
AU8196891A (en) 1990-06-25 1992-01-23 Immunex Corporation Mast cell growth factor
CA2125855C (en) * 1991-12-20 2008-05-13 Hans Holmegaard Sorensen A stabilized pharmaceutical formulation comprising growth hormone and histidine
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
ES2154650T3 (es) * 1992-10-02 2001-04-16 Genetics Inst Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador.

Also Published As

Publication number Publication date
US6288030B1 (en) 2001-09-11
CN1142771A (zh) 1997-02-12
AU696860B2 (en) 1998-09-17
US20020013258A1 (en) 2002-01-31
EP0732935A1 (de) 1996-09-25
ES2123951T3 (es) 1999-01-16
AU1442295A (en) 1995-07-10
IL112088A0 (en) 1995-03-15
NZ278252A (en) 1998-04-27
HK1008815A1 (en) 1999-05-21
CA2182970C (en) 2000-11-28
US5965522A (en) 1999-10-12
WO1995017206A1 (en) 1995-06-29
DE69414723T2 (de) 1999-07-22
EP0732935B1 (de) 1998-11-18
US6020469A (en) 2000-02-01
CA2182970A1 (en) 1995-06-29
DE69414723D1 (de) 1998-12-24
IL112088A (en) 2001-04-30
ZA9410189B (en) 1995-08-25
CN1105575C (zh) 2003-04-16
DK0732935T3 (da) 1999-08-02

Similar Documents

Publication Publication Date Title
DE69414723D1 (de) Lyophilisierte stammzellenfaktor formulierungen
FI952119A0 (fi) Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus
DK0758248T3 (da) Formuleringer til faktor IX
DE3778287D1 (de) Peptidische zusammensetzung.
GR3006172T3 (de)
DK289285A (da) Thymopentin analoge
AU5327386A (en) Peptide derivatives, analogous to pepstatin, which inhibit renin and acid proteases.
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
FI955130A0 (fi) L-aminohappo-oksidaasi
NO163619C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro- 2-heterocykloalkylpyrido(4,3)indoler.
ES2181763T3 (es) Formulaciones a base de fenbendazol.
ES2058479T3 (es) Compuestos peptidicos.
ATE41773T1 (de) 4,5-dihydro-4-oxo-2((2-transphenylcyclopropyl)amino>-3-furancarbonsaeuren und derivate davon.
FI945252A0 (fi) Stabiileja lyofilisoituja tiotepakoostumuksia
DE69521315D1 (de) Hirudin enthaltende pharmazeutische zusammensetzungen
DE3152363T1 (de)
NO164100C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-klor-s-triazolo-(4,3-a)-pyridin-7-carboxyl-syrer.
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
AU7117691A (en) Temporary minimal protection synthesis of lh-rh analogs
IT8423664A0 (it) Realizzate in applicazione al detto metodo per la produzione metodo. industriale di calzature, in particolare ciabatte, di notevole leggerezza ed utilizzabili sia da casa che all'aperto, e calzature
FI852990A0 (fi) Saosom antiarytmiska aemnen anvaendbara 2,5-pyrrolidindionderivat.
IT8420913A0 (it) Leggerezza ed utilizzabili sia da metodo per la produzione casa che all'aperto, e calzature industriale di calzature, in realizzate in applicazione al detto particolare ciabatte, di notevole metodo.
ATE74764T1 (de) Peptidische zusammensetzung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee